Ahmed Sadek, MD
Neurology · Orlando, FLNPI 1356327191
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by SK Life Science, Inc. at 25.6% of the total. Reporting peaked in 2019 at $7,456 and has fallen 91.5% since, to $636 in 2025.
Across 249 payments — averaging $108.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$7K
- UCB, Inc.$5K
- Greenwich Biosciences, Inc.$3K
- Sunovion Pharmaceuticals Inc.$3K
- Jazz Pharmaceuticals Inc.$3K
- Neuropace, Inc.$2K
- plus $4K from 23 others
Across 149 payments — averaging $6753.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$440K
- Amgen$230K
- H. Lundbeck A S$119K
- Jazz Pharmaceuticals Inc.$75K
- Livanova USA, Inc.$49K
- GW Research Limited$27K
- plus $66K from 4 others
What the payments were for
- Consulting fees$6,51524%
- Speaking & faculty fees$11,86644%
- Travel & lodging$1,3005%
- Food & beverage$6,95826%
- Education$3421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 18 | $6,916 |
| UCB, Inc. | 28 | $5,196 |
| Greenwich Biosciences, Inc. | 10 | $3,492 |
| Sunovion Pharmaceuticals Inc. | 24 | $3,480 |
| Jazz Pharmaceuticals Inc. | 8 | $2,802 |
| Neuropace, Inc. | 6 | $1,589 |
| AbbVie(2 entities) | 45 | $1,049 |
| Eisai Inc. | 16 | $543 |
| Teva Pharmaceuticals USA, Inc. | 21 | $464 |
| GE HealthCare | 14 | $294 |
| Supernus Pharmaceuticals, Inc. | 24 | $252 |
| EMD Serono, Inc. | 12 | $198 |
| Natus Medical Incorporated | 2 | $139 |
| Livanova USA, Inc. | 4 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $103 |
| Novartis | 3 | $45 |
| Neurelis, Inc. | 1 | $43 |
| Sanofi | 1 | $42 |
| Medtronic | 1 | $33 |
| Blueprint Medicines Corporation | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Amgen | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Aquestive Therapeutics, Inc. | 1 | $12 |
| Biogen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$5,989
- Fintepla$3,294
- XCOPRI$3,276
- Cenobamate$3,000
- APTIOM$2,971
- RNS System$1,472
- Fycompa$369
How this compares
$26,980 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Orlando
- Ramon Rodriguez CruzOrlando$1M
- Mark KlafterOrlando$247K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.